Patient with opc poisoning
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Here is a comprehensive clinical overview of organophosphate compound (OPC) poisoning:
Organophosphate (OPC) Poisoning
Mechanism
OPCs inhibit cholinesterase enzymes (acetylcholinesterase and pseudocholinesterase). This causes acetylcholine (ACh) accumulation at:
- Muscarinic receptors — parasympathetic postganglionic sites
- Nicotinic receptors — sympathetic/parasympathetic ganglia, adrenal medulla, neuromuscular junctions
- CNS receptors — NMDA receptors involved in seizure generation
A critical concept: "Aging" — the irreversible, permanent binding of OPC to cholinesterase. Once aging occurs, new enzyme must be resynthesized (weeks). Time to aging varies by agent (minutes for soman, >24 hours for others). Antidotes work only before aging occurs.
Clinical Features
Cholinergic Toxidrome Mnemonics:
| SLUDGE | DUMBELS | (Killer) Bs |
|---|---|---|
| Salivation | Defecation | Bradycardia |
| Lacrimation | Urination | Bronchorrhea |
| Urination | Miosis | Bronchospasm |
| Defecation | Bradycardia | |
| GI cramps | Emesis | |
| Emesis | Lacrimation/Salivation |
By receptor type:
| Receptor | Effects |
|---|---|
| Muscarinic | Salivation, lacrimation, urination, diarrhea, GI cramps, emesis, bradycardia, bronchospasm, bronchorrhea, miosis |
| Nicotinic (NMJ) | Muscle fasciculations → paralysis → respiratory arrest |
| Nicotinic (ganglia/adrenal) | Tachycardia, hypertension, diaphoresis, pallor, mydriasis |
| CNS | Anxiety, tremor, seizures, coma |
Parasympathetic effects usually predominate, but mixed autonomic signs are common.
Death typically results from respiratory failure — bronchorrhea + bronchospasm + respiratory muscle paralysis + pulmonary edema.
Clinical Syndromes (4 Types)
| Syndrome | Timing | Features |
|---|---|---|
| Acute poisoning | Within 8–24 h | Full cholinergic toxidrome |
| Intermediate syndrome | 1–5 days post-exposure (up to 40% of ingestion cases) | Neck flexors, cranial nerve muscles, proximal limbs, respiratory muscle paralysis — no cholinergic signs; may need ventilatory support; resolves in ~7 days |
| Organophosphate-induced delayed neuropathy (OPIDN) | Days to weeks | Cognitive dysfunction, peripheral neuropathy, extrapyramidal signs, autonomic dysfunction |
| Chronic toxicity | Ongoing low-level exposure | Symmetrical sensorimotor axonopathy mimicking Guillain-Barré |
Diagnosis
- Clinical diagnosis — treat immediately without waiting for labs if cholinergic toxidrome is present
- Characteristic garlic or hydrocarbon odor
- Plasma cholinesterase — falls first in acute poisoning
- RBC (erythrocyte) cholinesterase — more specific for chronic/cumulative exposure; takes up to 12 weeks to recover
- Metabolic acidosis → associated with higher mortality
- Both hyperglycemia and hypoglycemia at presentation are associated with worse outcomes
Differential Diagnosis
Carbamate pesticides, carbamate medications (e.g., rivastigmine), nicotine toxicity, cholinomimetics (pilocarpine), viral/bacterial gastroenteritis
Management
4 Goals of Treatment
- Decontamination
- Supportive care (airway priority)
- Reversal of ACh excess (atropine)
- Reversal of toxin binding (oximes/pralidoxime)
1. Decontamination
- Remove and destroy contaminated clothing
- Copious water flushing of skin — primary method
- No benefit from gastric lavage or activated charcoal (rapid absorption + profuse vomiting)
- Caregivers: Level C PPE (full-face respirator, chemical-resistant suit, nitrile/butyl rubber gloves)
- No role for hemodialysis or extracorporeal removal
2. Airway & Supportive Care
- Suction secretions, supplemental O₂, mechanical ventilation as needed
- For RSI: prefer rocuronium (1 mg/kg) over succinylcholine — succinylcholine is metabolized by cholinesterases and may have a prolonged effect (4–6 hours)
- Seizures → benzodiazepines (after airway secured)
- Tachycardia/dysrhythmias → treat underlying cholinergic excess, not with beta-blockers
3. Atropine (Muscarinic Antagonist)
| Parameter | Detail |
|---|---|
| Dose | 1–3 mg IV (0.05 mg/kg children), double every 5 min until bronchorrhea controlled |
| Endpoint | Drying of respiratory secretions, easing respiratory effort — NOT heart rate or pupil size |
| Total dose | May require 200–500 mg in the first hour |
| Maintenance | Infusion at 10–20% of total loading dose per hour |
| Note | Does NOT reverse nicotinic effects (muscle paralysis) |
4. Pralidoxime / 2-PAM (Oxime — Acetylcholinesterase Reactivator)
| Parameter | Detail |
|---|---|
| Indication | Moderate/severe poisoning requiring large/repeated atropine doses; respiratory depression, fasciculations, seizures, hemodynamic instability |
| Dose | 1–2 g IV bolus over 30 min (25–50 mg/kg pediatric), repeat up to hourly based on response |
| Alternative dosing | 2 g over 20 min → 500 mg/h infusion for up to 7 days |
| Mechanism | Binds OPC-cholinesterase complex → restores enzymatic activity |
| Critical | Must be given before aging occurs |
| Route | IV or IM (autoinjectors in military settings) |
Disposition
| Severity | Disposition |
|---|---|
| Minimal/asymptomatic | 6–8 hours ED observation, then discharge |
| Significant symptoms | ICU admission |
| Fat-soluble agents | May require weeks of supportive care and continuous pralidoxime infusion |
Recovery endpoint: absence of signs/symptoms when pralidoxime is withheld.
Sources:
- Rosen's Emergency Medicine, 10th Ed.
- Tintinalli's Emergency Medicine, 9th Ed.
This is a shared conversation. Sign in to Orris to start your own chat.